This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Allergan plc

Drug Names(s): Emselex (EU), darifenacin

Description: Enablex (Darifenacin) is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions including contraction of the urinary bladder smooth muscle and stimulation of salivary secretion.Enablex works by blocking the M3 receptor, which is primarily responsible for bladder muscle contraction. It is a potent muscarinic receptor antagonist that helps reduce incontinence episodes, increases the amount of urine thebladder can hold, reduces the frequency of urination episodes, and decreasesthe pressure or urgency associated with the urge to urinate.

Deal Structure: In July 2005, Novartis Pharmaceuticals Corporation and Procter & Gamble Pharmaceuticals entered into an agreement for the co-promotion and further development of Enablex in the United States. Novartis will continue to record revenues for Enablex and will pay royalties to P&GP based on the product's performance.

In August 2009, The Procter & Gamble Company and Warner Chilcott announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

Under the terms of the agreement, Warner Chilcott will acquire P&G's portfolio of branded pharmaceutical products, including Asacol HD, Actonel, and the co-promotion rights to Enablex, as well as P&G's prescription drug product pipeline and manufacturing facilities in Puerto Rico and Germany. In addition, the majority of the 2,300 employees working on P&G's pharmaceuticals business are expected to transfer to Warner Chilcott.

In October 2009, Warner Chilcott...See full deal structure in Biomedtracker

Partners: Novartis AG Merus Labs Inc.

Enablex News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug